103 related articles for article (PubMed ID: 8106073)
1. Effect of ebrotidine on gastric mucosal EGF and PDGF receptor expression.
Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A; Slomiany BL
Biochem Mol Biol Int; 1993 Aug; 30(6):1127-34. PubMed ID: 8106073
[TBL] [Abstract][Full Text] [Related]
2. Gastric mucosal EGF and PDGF receptor expression with ulcer healing by ebrotidine.
Slomiany BL; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
Am J Gastroenterol; 1994 Jun; 89(6):894-7. PubMed ID: 8198101
[TBL] [Abstract][Full Text] [Related]
3. Effect of GM1-ganglioside on gastric mucosal epidermal growth factor and platelet-derived growth factor receptor expression.
Slomiany BL; Liu J; Yao P; Piotrowski J; Grabska M; Slomiany A
Biochem Int; 1992 Jun; 27(1):97-104. PubMed ID: 1320885
[TBL] [Abstract][Full Text] [Related]
4. Effect of ebrotidine on gastric mucosal calcium channel activity.
Slomiany BL; Liu J; Kawai T; Czajkowski A; Slomiany A
Am J Gastroenterol; 1993 Jun; 88(6):881-6. PubMed ID: 8099251
[TBL] [Abstract][Full Text] [Related]
5. Regulation of gastric mucosal calcium channel activity by an antiulcer agent, ebrotidine.
Slomiany BL; Liu J; Piotrowski J; Czajkowski A; Yotsumoto F; Slomiany A
J Physiol Pharmacol; 1994 Mar; 45(1):121-31. PubMed ID: 7519082
[TBL] [Abstract][Full Text] [Related]
6. Gastroprotective properties of ebrotidine. A review.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):459-67. PubMed ID: 9205744
[TBL] [Abstract][Full Text] [Related]
7. Effect of ebrotidine on ethanol-induced gastric mucosal damage in the rat. Comparative study with other H2-receptor antagonists.
Palop D; Romero A; Villamayor F; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):450-4. PubMed ID: 9205742
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of EGF-induced gastric mucosal calcium channel phosphorylation by ebrotidine.
Slomiany BL; Liu J; Piotrowski J; Slomiany A
Biochem Int; 1992 Dec; 28(4):751-60. PubMed ID: 1282815
[TBL] [Abstract][Full Text] [Related]
9. Anti-Helicobacter pylori activities of ebrotidine. A review of biochemical and animal experimental studies and data.
Slomiany BL; Piotrowski J; Slomiany A
Arzneimittelforschung; 1997 Apr; 47(4A):475-82. PubMed ID: 9205747
[TBL] [Abstract][Full Text] [Related]
10. Gastroprotective and ulcer-healing activities of a new H2-receptor antagonist: ebrotidine.
Brzozowski T; Majka J; Konturek SJ
Digestion; 1992; 51(1):27-36. PubMed ID: 1353465
[TBL] [Abstract][Full Text] [Related]
11. Studies on the cytoprotective and antisecretory activity of ebrotidine. A review.
Konturek PC; Brzozowski T; Konturek SI; Márquez M; Torres J; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):578-89. PubMed ID: 9205769
[TBL] [Abstract][Full Text] [Related]
12. Enhancement in gastric mucosal epidermal growth factor receptor expression by sulglycotide.
Slomiany BL; Piotrowski J; Czajkowski A; Murty VL; Majka J; Slomiany A
Biochem Mol Biol Int; 1994 May; 33(2):229-34. PubMed ID: 7951043
[TBL] [Abstract][Full Text] [Related]
13. Histamine H2-receptor antagonist action of ebrotidine. Effects on gastric acid secretion, gastrin levels and NSAID-induced gastrotoxicity in the rat.
Palop D; Agut J; Márquez M; Conejo L; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):439-46. PubMed ID: 9205740
[TBL] [Abstract][Full Text] [Related]
14. Protamine inhibits platelet derived growth factor receptor activity but not epidermal growth factor activity.
Huang JS; Nishimura J; Huang SS; Deuel TF
J Cell Biochem; 1984; 26(4):205-20. PubMed ID: 6099364
[TBL] [Abstract][Full Text] [Related]
15. Ebrotidine--a new H2-receptor antagonist with mucosal strengthening activity.
Piotrowski J; Yamaki K; Morita M; Slomiany A; Slomiany BL
Biochem Int; 1992 Mar; 26(4):659-67. PubMed ID: 1351724
[TBL] [Abstract][Full Text] [Related]
16. Enhancement of gastric mucosal epidermal growth factor and platelet-derived growth factor receptor expression by sucralfate.
Slomiany BL; Liu J; Keogh JP; Piotrowski J; Slomiany A
Gen Pharmacol; 1992 Jul; 23(4):715-8. PubMed ID: 1397979
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation.
Lipson KE; Pang L; Huber LJ; Chen H; Tsai JM; Hirth P; Gazit A; Levitzki A; McMahon G
J Pharmacol Exp Ther; 1998 May; 285(2):844-52. PubMed ID: 9580635
[TBL] [Abstract][Full Text] [Related]
18. Action of ebrotidine, ranitidine and cimetidine on the specific binding to histamine H1- and H2-receptors.
Agut J; Sánchez JC; Sacristán A; Ortiz JA
Arzneimittelforschung; 1997 Apr; 47(4A):447-9. PubMed ID: 9205741
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin II stimulates rat astrocyte mitogen-activated protein kinase activity and growth through EGF and PDGF receptor transactivation.
Clark MA; Gonzalez N
Regul Pept; 2007 Dec; 144(1-3):115-22. PubMed ID: 17688958
[TBL] [Abstract][Full Text] [Related]
20. The platelet-derived-growth-factor receptor, not the epidermal-growth-factor receptor, is used by lysophosphatidic acid to activate p42/44 mitogen-activated protein kinase and to induce prostaglandin G/H synthase-2 in mesangial cells.
Goppelt-Struebe M; Fickel S; Reiser CO
Biochem J; 2000 Jan; 345 Pt 2(Pt 2):217-24. PubMed ID: 10620497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
